JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB97003

Goat Anti-Human IgG Fc (DyLight® 488)

Be the first to review this product! Submit a review

|

(10 Publications)

Suitable for IHC-P, Flow Cyt, ICC/IF. Cited in 10 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Fc region

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

DyLight® 488

Excitation/Emission

Ex: 493nm, Em: 518nm

Applications

ICC/IF, Flow Cyt, IHC-P

applications

Clonality

Polyclonal

Isotype

IgG

Specificity

By immunoelectrophoresis and ELISA this antibody reacts specifically with Human IgG. Cross reactivity with other immunoglobulins and light chains is less than 0.1%.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "IHC-P": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/50 - 1/500", "notes":"<p></p>" }, "Flow Cyt": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/50 - 1/200", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/50 - 1/500", "notes":"<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
Antiserum was solid phase adsorbed to ensure class specificity. This antibody was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to DyLight® 488.
Storage buffer
pH: 6.8 - 7.4 Preservative: 0.09% Sodium azide Constituents: PBS, 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

Additional targets

IGHG2,IGHG3,IGHG4

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:7926 PubMed40854890

2025

Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding.

Applications

Unspecified application

Species

Unspecified reactive species

Jinbo Li,Jiang Yu,Jia Song,Yingxi Zhang,Ning Li,Zhaomeng Wang,Meng Qin,Mingming Zhao,Baoyue Zhang,Ruiping Huang,Shuang Zhou,Yubo Liu,Zhonggui He,Hongzhuo Liu, Dan Liu,Yongjun Wang

Frontiers in immunology 14:1329540 PubMed38259458

2024

Case report: Overlapping anti-AMPAR encephalitis with anti-IgLON5 disease post herpes simplex virus encephalitis.

Applications

Unspecified application

Species

Unspecified reactive species

Shihui Sun,Jiafeng Ren,Zhao Zhong,Xuxia Ma,Danqing Shang,Changjun Su,Xianchao Zhao

International journal of molecular sciences 25: PubMed38256071

2024

The Abundant Distribution and Duplication of SARS-CoV-2 in the Cerebrum and Lungs Promote a High Mortality Rate in Transgenic hACE2-C57 Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Heng Li,Xin Zhao,Shasha Peng,Yingyan Li,Jing Li,Huiwen Zheng,Yifan Zhang,Yurong Zhao,Yuan Tian,Jinling Yang,Yibin Wang,Xinglong Zhang,Longding Liu

mAbs 15:2251190 PubMed37646089

2023

Mammalian display to secretion switchable libraries for antibody preselection and high throughput functional screening.

Applications

Unspecified application

Species

Unspecified reactive species

Ramona Gaa,Hannah Melina Mayer,Daniela Noack,Kavita Kumari,Ralf Guenther,Shang-Pu Tsai,Qingyong Ji,Achim Doerner

Frontiers in neurology 14:1201452 PubMed37346161

2023

Secondary immunoreaction in patients with neurosyphilis and its relevance to clinical outcomes.

Applications

Unspecified application

Species

Unspecified reactive species

Yaxiu Fang,Hong Wu,Guanghui Liu,Ziang Li,Dongmei Wang,Yuping Ning,Suyue Pan,Yafang Hu

Cells 11: PubMed36139437

2022

CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.

Applications

Unspecified application

Species

Unspecified reactive species

Zhijie Zhang,Chang Liu,Zhe Yang,Hongping Yin

Acta pharmaceutica Sinica. B 12:4446-4457 PubMed36561991

2022

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents.

Applications

Unspecified application

Species

Unspecified reactive species

Chengliang Sun,Yao Cheng,Xiaojia Liu,Gefei Wang,Wenjian Min,Xiao Wang,Kai Yuan,Yi Hou,Jiaxing Li,Haolin Zhang,Haojie Dong,Liping Wang,Chenguang Lou,Yanze Sun,Xinmiao Yu,Hongbin Deng,Yibei Xiao,Peng Yang

Frontiers in immunology 13:854445 PubMed35479088

2022

Identification of Anti-Collapsin Response Mediator Protein 2 Antibodies in Patients With Encephalitis or Encephalomyelitis.

Applications

Unspecified application

Species

Unspecified reactive species

Kaibiao Xu,Dongmei Wang,Yan He,Shengnan Wang,Guanghui Liu,Yue Pan,Haishan Jiang,Yu Peng,Fenliang Xiao,Yihua Huang,Qiqi Wang,Yongming Wu,Suyue Pan,Yafang Hu

mAbs 13:1978130 PubMed34586015

2021

Versatile and rapid microfluidics-assisted antibody discovery.

Applications

Unspecified application

Species

Unspecified reactive species

Ramona Gaa,Emmanuel Menang-Ndi,Shruti Pratapa,Christine Nguyen,Satyendra Kumar,Achim Doerner

Frontiers in immunology 12:666046 PubMed34305897

2021

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.

Applications

Unspecified application

Species

Unspecified reactive species

Yu Cai,Lu Han,Desheng Zhu,Jing Peng,Jianping Li,Jie Ding,Jiaying Luo,Ronghua Hong,Kan Wang,Wenbin Wan,Chong Xie,Xiajun Zhou,Ying Zhang,Yong Hao,Yangtai Guan
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com